In Japan, dabrafenib plus trametinib combination therapy was approved for BRAF V600E-positive solid tumors, including thyroid cancers, in November 2023, and another combination therapy, encorafenib plus binimetinib, was approved for BRAF V600E-positive thyroid cancers in May 2024 [4, 5]. Here, BRAF is linked to thyroid cancer.